KR102178692B1 - 암의 치료에서 유용한 6,7,8,9-테트라하이드로-3h-피라졸로[4,3-f]이소퀴놀린 유도체 - Google Patents

암의 치료에서 유용한 6,7,8,9-테트라하이드로-3h-피라졸로[4,3-f]이소퀴놀린 유도체 Download PDF

Info

Publication number
KR102178692B1
KR102178692B1 KR1020197014062A KR20197014062A KR102178692B1 KR 102178692 B1 KR102178692 B1 KR 102178692B1 KR 1020197014062 A KR1020197014062 A KR 1020197014062A KR 20197014062 A KR20197014062 A KR 20197014062A KR 102178692 B1 KR102178692 B1 KR 102178692B1
Authority
KR
South Korea
Prior art keywords
compound
formula
pharmaceutically acceptable
methyl
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197014062A
Other languages
English (en)
Korean (ko)
Other versions
KR20190066054A (ko
Inventor
제임스 스튜어트 스콧
버나드 크리스토프 바를라암
빈 양
토마스 앤드류 모스
사만다 제인 휴스
요하네스 빌헬무스 마리아 니씽크
다니엘 힐레브랜드 오'도노반
Original Assignee
아스트라제네카 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스트라제네카 아베 filed Critical 아스트라제네카 아베
Publication of KR20190066054A publication Critical patent/KR20190066054A/ko
Application granted granted Critical
Publication of KR102178692B1 publication Critical patent/KR102178692B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020197014062A 2016-10-24 2017-10-13 암의 치료에서 유용한 6,7,8,9-테트라하이드로-3h-피라졸로[4,3-f]이소퀴놀린 유도체 Active KR102178692B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662411799P 2016-10-24 2016-10-24
US62/411,799 2016-10-24
US201662435159P 2016-12-16 2016-12-16
US62/435,159 2016-12-16
PCT/EP2017/076191 WO2018077630A1 (en) 2016-10-24 2017-10-13 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer

Publications (2)

Publication Number Publication Date
KR20190066054A KR20190066054A (ko) 2019-06-12
KR102178692B1 true KR102178692B1 (ko) 2020-11-13

Family

ID=60083331

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197014062A Active KR102178692B1 (ko) 2016-10-24 2017-10-13 암의 치료에서 유용한 6,7,8,9-테트라하이드로-3h-피라졸로[4,3-f]이소퀴놀린 유도체

Country Status (37)

Country Link
US (5) US10131663B2 (OSRAM)
EP (2) EP3640251B1 (OSRAM)
JP (2) JP6744489B2 (OSRAM)
KR (1) KR102178692B1 (OSRAM)
CN (2) CN109843888B (OSRAM)
AU (1) AU2017349797B2 (OSRAM)
CA (1) CA3040040A1 (OSRAM)
CL (1) CL2019001077A1 (OSRAM)
CO (1) CO2019003950A2 (OSRAM)
CR (1) CR20190204A (OSRAM)
CY (2) CY1122566T1 (OSRAM)
DK (2) DK3433256T3 (OSRAM)
DO (1) DOP2019000104A (OSRAM)
EC (1) ECSP19028657A (OSRAM)
ES (2) ES2751902T3 (OSRAM)
HR (1) HRP20220255T1 (OSRAM)
HU (2) HUE057524T2 (OSRAM)
IL (1) IL266245B (OSRAM)
JO (1) JOP20190090B1 (OSRAM)
LT (2) LT3433256T (OSRAM)
ME (1) ME03547B (OSRAM)
MX (1) MX382331B (OSRAM)
MY (1) MY205300A (OSRAM)
NI (1) NI201900039A (OSRAM)
NZ (1) NZ753459A (OSRAM)
PE (1) PE20191078A1 (OSRAM)
PH (1) PH12019500830A1 (OSRAM)
PL (2) PL3640251T3 (OSRAM)
PT (2) PT3640251T (OSRAM)
RS (1) RS59445B1 (OSRAM)
SG (1) SG11201903182XA (OSRAM)
SI (2) SI3640251T1 (OSRAM)
SM (2) SMT201900602T1 (OSRAM)
TW (1) TWI735681B (OSRAM)
UA (1) UA125824C2 (OSRAM)
WO (1) WO2018077630A1 (OSRAM)
ZA (1) ZA201900694B (OSRAM)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745742C1 (ru) 2015-10-01 2021-03-31 Олема Фармасьютикалз, Инк. ТЕТРАГИДРО-1Н-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
JP7241542B2 (ja) * 2016-04-08 2023-03-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロイソキノリン エストロゲン受容体モジュレーター及びその使用
TW201803870A (zh) 2016-04-20 2018-02-01 阿斯特捷利康公司 化學化合物
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
SMT201900602T1 (it) 2016-10-24 2019-11-13 Astrazeneca Ab Derivato di 6,7,8,9-tetraidro-3h-pirazolo[4,3-f]isochinolina utile nel trattamento del cancro
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
PL3555097T3 (pl) 2016-12-16 2022-10-17 Janssen Pharmaceutica Nv Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
EP3689873B1 (en) 2017-01-30 2022-09-14 Astrazeneca AB Estrogen receptor modulators
WO2019002441A1 (en) * 2017-06-29 2019-01-03 Astrazeneca Ab CHEMICAL COMPOUNDS
WO2019002442A1 (en) * 2017-06-29 2019-01-03 Astrazeneca Ab CHEMICAL COMPOUNDS
ES2912740T3 (es) * 2017-11-14 2022-05-27 Kind Pharmaceutical Compuesto heterocíclico y aplicación del mismo en medicina
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
IL322405A (en) 2018-06-15 2025-09-01 Reata Pharmaceuticals Inc Decahydro-2h-naphth[1,2-d]imidazole compounds for inhibition of IL-17 and ROR-gamma
US12060340B2 (en) 2018-06-20 2024-08-13 Reata Pharmaceuticals, Inc Cysteine-dependent inverse agonists of nuclear receptors ROR-gamma/ROR-gamma-t and methods of treating diseases or disorders therewith
EP3837548A2 (en) 2018-08-17 2021-06-23 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for the treatment of breast cancer
CN109053524A (zh) * 2018-09-11 2018-12-21 山东谛爱生物技术有限公司 一种N-Boc-3-羟基氮杂环丁烷的制备方法
CN114302722A (zh) 2019-07-07 2022-04-08 奥列马制药公司 雌激素受体拮抗剂方案
AU2020407514A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations
EP4089094A4 (en) * 2020-01-10 2023-08-02 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine
KR20230005270A (ko) * 2020-04-24 2023-01-09 아스트라제네카 아베 약학적 제형
CN120267673A (zh) * 2020-04-24 2025-07-08 阿斯利康(瑞典)有限公司 用于治疗癌症的剂量方案
CN120665066A (zh) 2020-05-15 2025-09-19 南京再明医药有限公司 吡咯烷类化合物及其应用
CN115697987B (zh) * 2020-06-12 2025-08-05 海南先声再明医药股份有限公司 雌激素受体调节剂化合物及其用途
US12415799B2 (en) 2020-06-28 2025-09-16 Zhejiang Yangli Pharmaceutical Technology Co., Ltd. Indazole-fused cyclic compound
CN114105977B (zh) * 2020-08-28 2023-09-01 先声再明医药有限公司 雌激素受体调节剂化合物及其用途
KR20220107752A (ko) 2021-01-26 2022-08-02 충북대학교 산학협력단 피라졸로퀴놀린 유도체 및 이의 항암제로서의 용도
CN116669729A (zh) * 2021-02-08 2023-08-29 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
BR112023018286A2 (pt) 2021-03-11 2023-10-31 Janssen Pharmaceutica Nv Lorpucitinib para uso no tratamento de distúrbios mediados por jak
CN118679157A (zh) * 2021-12-28 2024-09-20 深圳扬厉医药技术有限公司 四氢环庚吲唑化合物的盐型、晶型
CN120051280A (zh) 2022-10-17 2025-05-27 阿斯利康(瑞典)有限公司 用于治疗癌症的serd的组合
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer
WO2024231548A1 (en) 2023-05-11 2024-11-14 Astrazeneca Ab Combination of a parp1 inhibitor and a selective estrogen degrader for treating cancer
WO2025175249A1 (en) * 2024-02-14 2025-08-21 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016097072A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2016202161A1 (zh) 2015-06-16 2016-12-22 江苏恒瑞医药股份有限公司 哌啶类衍生物、其制备方法及其在医药上的应用
WO2017174757A1 (en) 2016-04-08 2017-10-12 F. Hoffmann-La Roche Ag Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
US20170305909A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Chemical compounds

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
CN102060857A (zh) 2000-08-10 2011-05-18 辉瑞意大利有限公司 具有激酶抑制剂活性的二环吡唑类、其制备方法和包含它们的药物组合物
US20100113502A1 (en) 2005-03-22 2010-05-06 Astrazeneca Ab Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands
FR2884252B1 (fr) 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AR058223A1 (es) 2005-11-25 2008-01-23 Palau Pharma Sa Un comuesto de derivados de pirazoloisoquinolina, un procedimiento para l a preparacion de dicho compuesto y una composicion farmaceutica que comprende dicho compuesto
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2010138695A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
ES2826950T3 (es) 2009-05-27 2021-05-19 Ptc Therapeutics Inc Métodos para tratar cáncer y afecciones no neoplásicas
US20120157402A1 (en) 2009-05-27 2012-06-21 Liangxian Cao Methods for treating brain tumors
CA2800673A1 (en) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CA2819299A1 (en) * 2010-12-24 2012-06-28 Merck Sharp & Dohme B.V. N-substituted azetidine derivatives
EA029559B1 (ru) 2011-12-14 2018-04-30 Серагон Фармасьютикалс, Инк. Фторированные модуляторы рецепторов эстрогенов и их применение
UY35590A (es) 2013-05-28 2014-11-28 Astrazeneca Ab Nuevos compuestos para el tratamiento del cáncer
KR20160021277A (ko) 2013-06-19 2016-02-24 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조절제 및 이의 용도
CA2915534A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2015092634A1 (en) 2013-12-16 2015-06-25 Novartis Ag 1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
WO2016097073A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
WO2016097071A1 (en) * 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Estrogen receptor modulators and uses thereof
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
WO2016189011A1 (en) 2015-05-26 2016-12-01 F. Hoffmann-La Roche Ag Heterocyclic estrogen receptor modulators and uses thereof
CN106518768B (zh) 2015-09-15 2021-07-02 江苏恒瑞医药股份有限公司 丙烯酸类衍生物、其制备方法及其在医药上的应用
RU2745742C1 (ru) 2015-10-01 2021-03-31 Олема Фармасьютикалз, Инк. ТЕТРАГИДРО-1Н-ПИРИДО[3,4-b]ИНДОЛЬНЫЕ АНТИЭСТРОГЕННЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА
CN108349952A (zh) 2015-11-09 2018-07-31 豪夫迈·罗氏有限公司 四氢萘雌激素受体调节剂及其用途
JP6592197B2 (ja) 2015-11-12 2019-10-16 浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． アクリル酸誘導体、製造方法、および医薬としてのその使用
KR20180095564A (ko) 2015-12-22 2018-08-27 지앙수 헨그루이 메디슨 컴퍼니 리미티드 벤조피페리딘 유도체, 이의 제조 방법 및 이의 의학적 용도
WO2017182495A1 (en) * 2016-04-20 2017-10-26 Astrazeneca Ab Indazole derivatives that down-regulate the estrogen receptor and possess anti-cancer activity
WO2017192991A1 (en) 2016-05-06 2017-11-09 Xavier University Of Louisiana Selective estrogen receptor down-regulators (serds)
WO2018001232A1 (zh) 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
WO2018019793A1 (en) 2016-07-25 2018-02-01 Astrazeneca Ab N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
CN107814798B (zh) 2016-09-14 2020-11-03 四川科伦博泰生物医药股份有限公司 3-取代丙烯酸类化合物及其制备方法和用途
WO2018053354A1 (en) 2016-09-15 2018-03-22 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
SMT201900602T1 (it) * 2016-10-24 2019-11-13 Astrazeneca Ab Derivato di 6,7,8,9-tetraidro-3h-pirazolo[4,3-f]isochinolina utile nel trattamento del cancro
BR102016024814A2 (pt) 2016-10-24 2018-05-08 Aché Laboratórios Farmacêuticos S.A. composto, processo de obtenção do composto, composição farmacêutica, uso do composto e método de tratamento de desordens psiquiátricas e/ou distúrbios do sono
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
PE20191501A1 (es) 2016-12-16 2019-10-22 Pfizer Agonistas receptores de glp-1 y sus usos de los mismos
PL3555097T3 (pl) 2016-12-16 2022-10-17 Janssen Pharmaceutica Nv Związki imidazo[4,5-d]pirolo[2,3-b]pirydynowe jako inhibitory kinaz janusowych
RS61108B1 (sr) 2016-12-16 2020-12-31 Lilly Co Eli Jedinjenja 7-feniletilamino-4h-pirimido[4,5-d][1,3]oksazin-2-ona kao inhibitori idh1 i idh2 mutanta
CN110291072A (zh) 2016-12-16 2019-09-27 巴斯夫欧洲公司 农药化合物
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
JP7208142B2 (ja) 2017-01-30 2023-01-18 シエッシ ファーマスーティシ エス．ピー．エー． Ｒｈｏキナーゼ阻害剤としてのチロシンアミド誘導体

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016097072A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
WO2016202161A1 (zh) 2015-06-16 2016-12-22 江苏恒瑞医药股份有限公司 哌啶类衍生物、其制备方法及其在医药上的应用
WO2017174757A1 (en) 2016-04-08 2017-10-12 F. Hoffmann-La Roche Ag Tetrahydroisoquinoline estrogen receptor modulators and uses thereof
US20170305909A1 (en) 2016-04-20 2017-10-26 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
CY1125292T1 (el) 2024-02-16
CA3040040A1 (en) 2018-05-03
CL2019001077A1 (es) 2019-06-21
ME03547B (me) 2020-07-20
US10961241B2 (en) 2021-03-30
ES2907759T3 (es) 2022-04-26
MX382331B (es) 2025-03-13
HUE045714T2 (hu) 2020-01-28
JP2019537570A (ja) 2019-12-26
DOP2019000104A (es) 2019-05-15
SI3640251T1 (sl) 2022-04-29
TWI735681B (zh) 2021-08-11
JP6993477B2 (ja) 2022-01-13
PL3433256T3 (pl) 2020-01-31
US20190100520A1 (en) 2019-04-04
US12077530B2 (en) 2024-09-03
DK3433256T3 (da) 2019-10-28
CR20190204A (es) 2019-06-11
MX2019004685A (es) 2019-08-21
DK3640251T3 (da) 2022-03-07
PT3640251T (pt) 2022-02-22
KR20190066054A (ko) 2019-06-12
IL266245B (en) 2021-05-31
TW201829403A (zh) 2018-08-16
HRP20220255T1 (hr) 2022-04-29
JOP20190090A1 (ar) 2019-04-23
SI3433256T1 (sl) 2019-11-29
NZ753459A (en) 2023-01-27
CN114656464B (zh) 2024-10-15
US20210284636A1 (en) 2021-09-16
RS59445B1 (sr) 2019-11-29
US10590130B2 (en) 2020-03-17
IL266245A (en) 2019-06-30
US20180111931A1 (en) 2018-04-26
MY205300A (en) 2024-10-11
WO2018077630A1 (en) 2018-05-03
HUE057524T2 (hu) 2022-05-28
ZA201900694B (en) 2024-09-25
BR112019007393A2 (pt) 2019-07-02
UA125824C2 (uk) 2022-06-15
AU2017349797B2 (en) 2020-05-21
CO2019003950A2 (es) 2019-04-30
NI201900039A (es) 2020-05-15
ES2751902T3 (es) 2020-04-02
LT3640251T (lt) 2022-03-10
LT3433256T (lt) 2019-11-11
CY1122566T1 (el) 2021-01-27
US20240383895A1 (en) 2024-11-21
JP2020186250A (ja) 2020-11-19
EP3433256A1 (en) 2019-01-30
CN109843888A (zh) 2019-06-04
JOP20190090B1 (ar) 2023-03-28
SG11201903182XA (en) 2019-05-30
PL3640251T3 (pl) 2022-04-11
PE20191078A1 (es) 2019-08-20
US10131663B2 (en) 2018-11-20
PH12019500830A1 (en) 2019-07-24
CN109843888B (zh) 2022-03-01
EP3433256B1 (en) 2019-08-07
EP3640251A1 (en) 2020-04-22
PT3433256T (pt) 2019-10-31
SMT202200098T1 (it) 2022-03-21
ECSP19028657A (es) 2019-04-30
SMT201900602T1 (it) 2019-11-13
CN114656464A (zh) 2022-06-24
US20200239467A1 (en) 2020-07-30
EP3640251B1 (en) 2021-12-08
AU2017349797A1 (en) 2019-05-30
JP6744489B2 (ja) 2020-08-19

Similar Documents

Publication Publication Date Title
KR102178692B1 (ko) 암의 치료에서 유용한 6,7,8,9-테트라하이드로-3h-피라졸로[4,3-f]이소퀴놀린 유도체
WO2018019793A1 (en) N-(2-(4-((1r,3r)-3-methyl-2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indol-1-yl)phenoxy)ethyl)propan-1-amine derivatives and related compounds as selective down-regulators of the estrogen receptor for treating cancer
WO2017182493A1 (en) Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer
EP3494116B1 (en) Estrogen receptor modulators
HK40026812A (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
HK40026812B (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
EA037533B1 (ru) 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА
HK40002601B (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivative useful in the treatment of cancer
HK40002601A (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivative useful in the treatment of cancer
RS62937B1 (sr) Derivati 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izohinolina korisni u tretmanu raka
BR112019007393B1 (pt) Compostos 6,7,8,9-tetra-hidro-3h-pirazolo[4,3-]isoquinolina úteis no tratamento de câncer, uso dos mesmos, combinação, uso da combinação e composição farmaceutica

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190516

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200511

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20200511

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20200824

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20201109

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20201109

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20231004

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240927

Start annual number: 5

End annual number: 5